次に

自動再生

Highlights from ASCO 2016 for myeloproliferative neoplasms

4 ビュー • 07/29/23
シェア
埋め込む
administrator
administrator
加入者
0

Ruben Mesa, MD from the Mayo Clinic, Phoenix, AZ talks about his highlights from the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. In particular, Dr Mesa discusses why he is looking forward to hearing about key drugs in disease areas that are relevant to myeloproliferative neoplasms (MPNs), which include acute leukemias and myelodysplastic syndrome (MDS). According to Dr Mesa, the data on immunotherapy and intercellular therapy in these areas is of interest. For MPNs, he highlights the five year update on the safety and efficacy of ruxolitinib.

もっと見せる
0 コメント sort 並び替え
フェイスブックのコメント

次に

自動再生